Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beam Therapeutics (BEAM) Non-Current Deffered Revenue (2020 - 2025)

Beam Therapeutics (BEAM) has disclosed Non-Current Deffered Revenue for 6 consecutive years, with $10.2 million as the latest value for Q3 2025.

  • On a quarterly basis, Non-Current Deffered Revenue fell 82.43% to $10.2 million in Q3 2025 year-over-year; TTM through Sep 2025 was $10.2 million, a 82.43% decrease, with the full-year FY2024 number at $33.2 million, down 69.77% from a year prior.
  • Non-Current Deffered Revenue was $10.2 million for Q3 2025 at Beam Therapeutics, down from $20.3 million in the prior quarter.
  • In the past five years, Non-Current Deffered Revenue ranged from a high of $262.3 million in Q4 2021 to a low of $10.2 million in Q3 2025.
  • A 5-year average of $115.7 million and a median of $104.7 million in 2023 define the central range for Non-Current Deffered Revenue.
  • Peak YoY movement for Non-Current Deffered Revenue: soared 66474.37% in 2021, then plummeted 82.43% in 2025.
  • Beam Therapeutics' Non-Current Deffered Revenue stood at $262.3 million in 2021, then dropped by 22.92% to $202.2 million in 2022, then crashed by 45.65% to $109.9 million in 2023, then plummeted by 69.77% to $33.2 million in 2024, then crashed by 69.41% to $10.2 million in 2025.
  • Per Business Quant, the three most recent readings for BEAM's Non-Current Deffered Revenue are $10.2 million (Q3 2025), $20.3 million (Q2 2025), and $49.4 million (Q1 2025).